Retatrutide vs Semaglutide vs Tirzepatide: Research Comparison

Semaglutide, tirzepatide and retatrutide are three peptides from the incretin field that are most easily understood by counting the receptors each one activates. Semaglutide engages a single receptor (GLP-1); tirzepatide engages two (GLP-1 and GIP); retatrutide engages three (GLP-1, GIP and glucagon). That ladder — one, two, three — is the cleanest way to tell them apart, and each added receptor changes what the compound is studied for in the metabolic research literature. This article compares the three for research identification only and makes no claim about human use, safety, or benefit.

Receptor targets at a glance

The shared starting point: incretin signalling

All three compounds sit inside the incretin system — the gut-hormone signalling axis that links nutrient intake to insulin release. Two receptors do most of the work in this pathway: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Native incretin hormones are cleared from the body within minutes, so each of these peptides is engineered with a fatty-acid modification that binds reversibly to albumin and extends the circulating half-life to roughly a week, which is why they are studied as once-weekly research compounds rather than continuous infusions. Our incretin receptor signalling category groups these and related compounds by the receptors they engage.

Semaglutide: single GLP-1 receptor

Semaglutide is a modified GLP-1 analog that engages one receptor: GLP-1. In the published literature it is described as acting across the pancreas, gastrointestinal tract and central appetite circuits, where GLP-1 signalling is associated with glucose-dependent insulin secretion, suppression of glucagon, slowed gastric emptying, and central satiety pathways. Because it targets a single receptor, semaglutide is the reference point against which the multi-receptor compounds are usually compared. As a molecule it is the most extensively studied of the three, with published human trial programmes as well as preclinical work; the corresponding approved branded medicines are a separate, regulated category and are not what is offered here. You can survey the primary literature through a semaglutide PubMed search.

Tirzepatide: dual GLP-1 / GIP

Tirzepatide (investigational code LY3298176) is a single 39-amino-acid peptide that activates two receptors at once — GLP-1 and GIP. The GLP-1 arm covers the same appetite and gastric-emptying signalling associated with semaglutide, while the added GIP arm is studied for its role in insulin sensitivity and adipose-tissue nutrient handling. Structural work has described tirzepatide as an imbalanced or biased dual agonist: it mimics native GIP closely at the GIP receptor but signals differently at the GLP-1 receptor, favouring cAMP generation over receptor internalisation (tirzepatide PubMed search). Tirzepatide is discussed here only to complete the mechanistic picture — Amrita Peptides does not stock it, and there is no tirzepatide product page. It is the conceptual bridge between the single-receptor and triple-receptor compounds.

Retatrutide: triple GLP-1 / GIP / glucagon

Retatrutide (investigational code LY3437943) extends the ladder one rung further by adding glucagon-receptor activation alongside GLP-1 and GIP, making it a triple-receptor agonist. The GLP-1 and GIP arms function much as they do in tirzepatide, but the glucagon component is the outlier: in the research literature glucagon-receptor signalling is associated with hepatic fatty-acid oxidation and basal metabolic rate — the energy-expenditure side of metabolism rather than the intake side. Simultaneous GLP-1 activation is described as offsetting glucagon's tendency to raise blood glucose. Retatrutide is the newest of the three and remains investigational, characterised in phase 2 studies with later-stage programmes ongoing (retatrutide PubMed search). For a Thailand-specific overview of how it is handled and sourced for laboratory work, see our retatrutide research guide.

Why the receptor count matters in the literature

The reason researchers pay attention to receptor count is that each added receptor engages a genuinely separate physiological lever rather than a redundant one:

• GLP-1 is associated primarily with appetite signalling and gastric emptying.
• GIP is associated with insulin sensitivity and how adipose tissue handles nutrients.
• Glucagon is the outlier — instead of reducing intake, it is linked to hepatic fatty-acid oxidation and resting energy expenditure.

This is why retatrutide is framed in the literature as a mechanistically distinct compound rather than simply a stronger version of tirzepatide: it is the only one of the three that acts meaningfully on the expenditure side of energy balance. Moving up the ladder is not just "more of the same signal" — it recruits additional, qualitatively different pathways, which is exactly what makes the one/two/three framing informative rather than cosmetic.

A note on head-to-head comparisons

No single published trial has compared all three compounds against one another in the same population, under the same protocol. Any figures that circulate come from separate studies with different designs, durations and endpoints, so they describe broad mechanistic and trial-level trends, not a controlled ranking. Treat the receptor-count progression as a map of how the mechanisms differ, not as a scoreboard.

Buying and handling for research in Thailand

The three compounds should not be assigned one generic solvent, temperature, or shelf-life rule. Use material-specific evidence or a validated protocol, supported by the reconstitution guide and Thailand storage guide. An RUO label does not establish legal status; check the Thai FDA's current import information for the specific product and transaction.